Cristina Ivan

List of Publications by Year
in descending order

144	11,719	25014	30058
papers	citations	57	103
		h-index	g-index

153	153	153	21228
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. Cancer Cell, 2014, 26, 707-721.	7.7	1,293
2	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
3	PDL1 Regulation by p53 via miR-34. Journal of the National Cancer Institute, 2016, 108, .	3.0	475
4	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	0.6	463
5	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	5.8	363
6	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	298
7	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4394-4399.	3.3	222
8	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology, 2015, 17, 311-321.	4.6	205
9	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, 5203.	5.8	195
10	TP53 loss creates therapeutic vulnerability inÂcolorectal cancer. Nature, 2015, 520, 697-701.	13.7	192
11	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood, 2013, 122, 1891-1899.	0.6	184
12	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology, 2012, 142, 886-896.e9.	0.6	174
13	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget, 2013, 4, 1748-1762.	0.8	169
14	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	5.8	169
15	Autocrine Effects of Tumor-Derived Complement. Cell Reports, 2014, 6, 1085-1095.	2.9	164
16	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 2016, 18, 639-648.	0.6	161
17	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine, 2018, 38, 100-112.	2.7	159
18	Prooncogenic Factors miR-23b and miR-27b Are Regulated by Her2/Neu, EGF, and TNF-Î± in Breast Cancer. Cancer Research, 2013, 73, 2884-2896.	0.4	158

#	Article	IF	Citations
19	miRâ€203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Molecular Oncology, 2014, 8, 83-92.	2.1	156
20	Role of Focal Adhesion Kinase in Regulating YBâ€“1â€“Mediated Paclitaxel Resistance in Ovarian Cancer. Journal of the National Cancer Institute, 2013, 105, 1485-1495.	3.0	151
21	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications, 2014, 5, 5202.	5.8	151
22	FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018, 9, 2923.	5.8	151
23	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142
24	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	7.7	140
25	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	3.2	122
26	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Research, 2016, 76, 7194-7207.	0.4	118
27	Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNÎ³ secretion. Cancer Letters, 2018, 430, 47-56.	3.2	117
28	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	6.1	111
29	MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. British Journal of Cancer, 2014, 110, 1614-1621.	2.9	109
30	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Î²-Catenin Signaling in Colorectal Cancer. EBioMedicine, 2016, 13, 113-124.	2.7	106
31	Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget, 2015, 6, 29161-29177.	0.8	105
32	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	2.9	105
33	2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	5.8	103
34	HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants and Redox Signaling, 2014, 21, 1220-1238.	2.5	102
35	Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Molecular Cancer Therapeutics, 2015, 14, 2260-2269.	1.9	100
36	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications, 2016, 7, 11169.	5.8	100

#	Article	IF	Citations
37	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	3.8	97
38	Clinically Relevant microRNAs in Ovarian Cancer. Molecular Cancer Research, 2015, 13, 393-401.	1.5	90
39	NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis. Cancer Research, 2016, 76, 3145-3155.	0.4	87
40	The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression. Cell Reports, 2014, 8, 1447-1460.	2.9	86
41	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene, 2016, 35, 4312-4320.	2.6	83
42	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget, 2017, 8, 11641-11658.	0.8	81
43	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling, 2020, 68, 109539.	1.7	81
44	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3280-3288.	3.2	80
45	Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut, 2020, 69, 1818-1831.	6.1	80
46	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	0.6	75
47	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene, 2016, 35, 2390-2397.	2.6	71
48	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw026.	3.0	70
49	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 1713-1724.	3.2	69
50	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. Clinical Cancer Research, 2017, 23, 1323-1333.	3.2	67
51	Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer. Clinical Cancer Research, 2011, 17, 7283-7293.	3.2	65
52	miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. Clinical Cancer Research, 2017, 23, 5255-5266.	3.2	65
53	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clinical Cancer Research, 2018, 24, 4225-4241.	3.2	64
54	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35, 4914-4926.	2.6	63

#	Article	IF	Citations
55	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nature Communications, 2018, 9, 461.	5.8	61
56	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016, 7, 15093-15104.	0.8	61
57	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 2127-2137.	3.2	60
58	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.4	59
59	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Research, 2018, 28, 432-447.	2.4	58
60	Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche. Cancer Research, 2018, 78, 2990-3001.	0.4	57
61	TRPA1â€“FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. Nature Communications, 2017, 8, 947.	5.8	56
62	Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy - Nucleic Acids, 2017, 9, 251-262.	2.3	56
63	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget, 2017, 8, 20145-20164.	0.8	56
64	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 2119-2130.	3.9	56
65	p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle, 2012, 11, 3433-3442.	1.3	54
66	MALAT1 promoted invasiveness of gastric adenocarcinoma. BMC Cancer, 2017, 17, 46.	1.1	54
67	Circular <scp>RNA</scp>s: Methodological challenges and perspectives in cardiovascular diseases. Journal of Cellular and Molecular Medicine, 2018, 22, 5176-5187.	1.6	54
68	Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer. Molecular Cancer, 2018, 17, 100.	7.9	52
69	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Research, 2019, 21, 20.	2.2	52
70	Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute, 2016, 108, djv426.	3.0	51
71	The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications, 2015, 6, 7351.	5.8	48
72	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 448-459.	3.2	48

#	Article	IF	Citations
73	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. Frontiers in Cell and Developmental Biology, 2020, 8, 50.	1.8	48
74	Dirac operators and spectral triples for some fractal sets built on curves. Advances in Mathematics, 2008, 217, 42-78.	0.5	47
75	microRNAs in Cancer. Advances in Cancer Research, 2010, 108, 113-157.	1.9	43
76	Cellular and Kaposiâ€™s sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. Cell Death and Disease, 2014, 5, e1559-e1559.	2.7	43
77	Epsteinâ€“Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine, 2015, 2, 572-582.	2.7	43
78	Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. PLoS Biology, 2017, 15, e2002623.	2.6	41
79	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene, 2019, 38, 6095-6108.	2.6	40
80	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunology Research, 2019, 7, 2036-2051.	1.6	39
81	Targeting Src and Tubulin in Mucinous Ovarian Carcinoma. Clinical Cancer Research, 2013, 19, 6532-6543.	3.2	38
82	Ultraconserved long non-coding RNA uc.63 in breast cancer. Oncotarget, 2017, 8, 35669-35680.	0.8	38
83	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2017, 2, .	2.3	38
84	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	1.6	37
85	Regulation of hnRNPA1 by microRNAs controls the miR-18aâ€“K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discovery, 2017, 3, 17029.	3.1	36
86	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	5.8	36
87	PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine, 2019, 40, 290-304.	2.7	36
88	ApoptomiRs expression modulated by BCRâ€“ABL is linked to CML progression and imatinib resistance. Blood Cells, Molecules, and Diseases, 2014, 53, 47-55.	0.6	35
89	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget, 2015, 6, 7262-7279.	0.8	35
90	Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene, 2018, 37, 722-731.	2.6	34

#	Article	IF	Citations
91	FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. Non-coding RNA, 2020, 6, 41.	1.3	34
92	Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. Journal of the American Chemical Society, 2021, 143, 7655-7670.	6.6	34
93	Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia, 2018, 32, 920-930.	3.3	32
94	Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecologic Oncology, 2013, 128, 506-511.	0.6	29
95	Regulating the stability and localization of CDK inhibitor p27^{Kip1} via CSN6-COP1 axis. Cell Cycle, 2015, 14, 2265-2273.	1.3	29
96	Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer. Neoplasia, 2016, 18, 689-698.	2.3	27
97	EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene, 2019, 38, 2123-2134.	2.6	27
98	Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene, 2016, 35, 2186-2196.	2.6	26
99	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Science Advances, 2021, 7, .	4.7	26
100	Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nature Communications, 2020, 11, 4840.	5.8	25
101	Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albuminâ€“Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2014, 13, 2583-2594.	1.9	24
102	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget, 2018, 9, 25115-25126.	0.8	24
103	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology, 2013, 3, 58.	1.3	23
104	OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Scientific Reports, 2018, 8, 13106.	1.6	23
105	PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	1.9	23
106	VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells. Molecular Cancer Research, 2015, 13, 1274-1282.	1.5	21
107	Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. Cancers, 2021, 13, 3450.	1.7	21
108	Spectral triples and the geometry of fractals. Journal of Noncommutative Geometry, 2012, 6, 249-274.	0.3	20

#	Article	IF	Citations
109	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics, 2015, 14, 1466-1475.	1.9	20
110	Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine, 2017, 20, 182-192.	2.7	19
111	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight, 2020, 5, .	2.3	18
112	Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. Oncotarget, 2014, 5, 8492-8502.	0.8	18
113	The nonâ€coding RNome after splenectomy. Journal of Cellular and Molecular Medicine, 2019, 23, 7844-7858.	1.6	17
114	The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene, 2021, 40, 384-395.	2.6	17
115	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. Oncotarget, 2014, 5, 1185-1197.	0.8	17
116	Sums of two-dimensional spectral triples. Mathematica Scandinavica, 2007, 100, 35.	0.1	17
117	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. Journal of Clinical Investigation, 2022, 132, .	3.9	17
118	Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget, 2017, 8, 10905-10918.	0.8	15
119	targetHub: a programmable interface for miRNAâ€“gene interactions. Bioinformatics, 2013, 29, 2657-2658.	1.8	14
120	Clinically relevant inflammatory breast cancer patient-derived xenograftâ€“derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE, 2018, 13, e0195932.	1.1	13
121	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. International Journal of Molecular Sciences, 2021, 22, 1882.	1.8	13
122	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. Nature Communications, 2020, 11, 4755.	5.8	12
123	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight, 2016, 1, e87754.	2.3	11
124	Expression pattern of FGFR2, Grb2 and Plcĵ31 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. American Journal of Cancer Research, 2015, 5, 3135-48.	1.4	11
125	Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, 63, 1566-1579.	0.6	11
126	A genomeâ€scale screen reveals contextâ€dependent ovarian cancer sensitivity to mi <scp>RNA</scp> overexpression. Molecular Systems Biology, 2015, 11, 842.	3.2	10

#	Article	IF	Citations
127	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Molecular Cancer Therapeutics, 2019, 18, 421-436.	1.9	10
128	Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer. , 2021, 9, e002682.		10
129	Low spinophilin expression enhances aggressive biological behavior of breast cancer. Oncotarget, 2015, 6, 11191-11202.	0.8	10
130	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. Journal of the National Cancer Institute, 2017, 109, .	3.0	9
131	Profiling the circulating miRnome reveals a temporal regulation of the bone injury response. Theranostics, 2018, 8, 3902-3917.	4.6	9
132	A novel lncRNA derived from an ultraconserved region: lnc-uc.147, a potential biomarker in luminal A breast cancer. RNA Biology, 2021, , 1-14.	1.5	9
133	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. Journal of the National Cancer Institute, 2020, 112, 266-277.	3.0	5
134	KRCC1: A potential therapeutic target in ovarian cancer. FASEB Journal, 2020, 34, 2287-2300.	0.2	5
135	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecologic Oncology, 2021, 163, 181-190.	0.6	5
136	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Molecular Cancer Therapeutics, 2021, 20, 2352-2361.	1.9	5
137	Extensions and Degenerations of Spectral Triples. Communications in Mathematical Physics, 2009, 285, 925-955.	1.0	4
138	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. Journal of Neuro-Oncology, 2018, 136, 33-39.	1.4	4
139	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Molecular Cancer Therapeutics, 2018, 17, 464-473.	1.9	4
140	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget, 2020, 11, 2819-2833.	0.8	4
141	Gene Body Methylation of the Lymphocyte-Specific GeneCARD11Results in Its Overexpression and Regulates Cancer mTOR Signaling. Molecular Cancer Research, 2022, 19, 1917-1928.	1.5	3
142	Transcribed Ultraconserved Regions Are Associated with Clinicopathological Features in Breast Cancer. Biomolecules, 2022, 12, 214.	1.8	3
143	lncRNAs UC.145 and PRKG1-AS1 Determine the Functional Output of DKK1 in Regulating the Wnt Signaling Pathway in Gastric Cancer. Cancers, 2022, 14, 2369.	1.7	2
144	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 5411-5411.	3.9	0